Belén Garijo, Merck KGaA CEO (Arne Dedert/picture alliance via Getty Images)
US sales for Merck KGaA’s Bavencio impacted by Padcev/Keytruda momentum in bladder cancer
Following the standing ovation for Seagen and Astellas’ Padcev in combination with Merck’s Keytruda at last year’s ESMO Congress, Merck KGaA is seeing US sales …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.